Gsa Capital Partners LLP Syndax Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$11.39 - $21.67 $280,866 - $534,360	24,659 New	24,659 $532,000
Q2 2022 Aug 09, 2022	SELL	$13.64 - $19.48 $433,179 - $618,645	-31,758 Reduced 73.34%	11,542 $222,000
Q1 2022 May 11, 2022	BUY	$14.84 - $22.15 $642,572 - $959,094	43,300 New	43,300 $753,000
Q1 2021 May 10, 2021	SELL	$19.28 - $24.59 $461,910 - $589,127	-23,958 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$15.1 - $26.44 $203,276 - $355,935	-13,462 Reduced 35.98%	23,958 $533,000
Q3 2020 Nov 06, 2020	BUY	$13.39 - $17.48 $501,053 - $654,101	37,420 New	37,420 $552,000
Q1 2020 May 12, 2020	SELL	$6.65 - $12.03 $153,222 - $277,183	-23,041 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$5.43 - $9.22 $125,112 - $212,438	23,041 New	23,041 $202,000
Q3 2019 Nov 12, 2019	SELL	$7.47 - $10.76 $183,388 - $264,158	-24,550 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$4.9 - $9.31 $45,212 - $85,903	9,227 Added 60.22%	24,550 $229,000
Q1 2019 May 15, 2019	BUY	$4.26 - $6.86 $65,275 - $105,115	15,323 New	15,323 $80,000
Q3 2018 Nov 13, 2018	SELL	$6.33 - $8.08 $331,692 - $423,392	-52,400 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$6.93 - $14.63 $363,132 - $766,612	52,400 New	52,400 $368,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $910M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.